You just read:

Crescendo Biologics' Receives Further Investment from Astellas Venture Management to Develop Novel Humabody™ Therapeutics Targeting Immune Checkpoint Inhibitors

News provided by

Crescendo Biologics

16 Dec, 2014, 09:00 GMT